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A novel prion protein 
variant in a patient with 
semantic dementia
Prion diseases are a group of fatal neuro-
degenerative diseases that can be sporadic, 
inherited or acquired. Inherited prion 
diseases are caused by mutations in the 
prion protein gene, PRNP, usually single 
nucleotide substitutions or structural vari-
ants of an octapeptide repeat encoding 
region. Although the classical presenta-
tion of sporadic Creutzfeldt Jakob disease 
(CJD) is rapidly progressive ataxia, 
myoclonus and cognitive decline, the 
presentation of genetic cases is variable 
and decline can be much slower.
Prion diseases can mimic many neuro-
degenerative diseases. Genetic dementias 
are pleiotropic, with similar clinical 
syndromes being caused by mutations in 
different genes; additionally, mutations 
in a single gene may cause diverse clin-
ical phenotypes. Due to the diagnostic 
difficulties arising from this clinical 
and genetic heterogeneity, next-genera-
tion sequencing technologies including 
gene panels and exome sequencing are 
helpful in elucidating genetic causes of 
dementia.1
Here we report a novel variant in PRNP 
in a patient diagnosed with semantic 
dementia, a variant of frontotemporal 
dementia (FTD). Patients with semantic 
dementia develop progressive loss of 
semantic knowledge resulting in significant 
early language impairment, with subse-
quent wider cognitive impairment and 
behavioural problems. MRI appearances 
are characteristic with focal asymmetric 
anteroinferior temporal lobe atrophy. The 
predominant histopathological finding is 
accumulation of Tar DNA-binding protein 
43 (TDP-43) deposits in the temporal and 
frontal lobes, although other pathologies, 
including Alzheimer’s disease, are occa-
sionally observed.2 A Mendelian genetic 
aetiology is rarely documented.
A woman in her seventh decade 
presented with a 1-year history of rapidly 
progressive language problems and 
behavioural change. She had particular 
difficulty naming objects and suffered 
from impaired comprehension, but had 
preserved recognition of faces and episodic 
memory. Over the same time period her 
personality changed, becoming disinhib-
ited and exhibiting obsessional behaviour. 
She also struggled with cooking but not 
with self-care or housework. She had no 
significant surgical or medical history, 
apart from a 5-year history of tinnitus and 
deafness, and took no regular medications.
A family history of dementia was 
known: her mother developed dementia 
of uncertain aetiology in her seventh 
decade, which progressed steadily with 
a total duration of 10 years. Her father 
died in his eighth decade of a myocardial 
infarction. There was no other relevant 
family history.
Physical examination revealed bilat-
eral sensorineural hearing loss, globally 
brisk tendon reflexes, positive pout reflex 
and mild bilateral limb apraxia, but was 
otherwise unremarkable. She scored 
23/30 on Mini-Mental State Examination 
(MMSE). On formal neuropsychometric 
testing, she obtained a verbal IQ of 66 and 
performance IQ of 78. Testing of specific 
cognitive domains revealed significantly 
impaired single word comprehension 
(Peabody Picture Vocabulary Test) and 
anomia (Oldfield Naming Test), as well 
as a surface dyslexia and dysgraphia, 
consistent with an impairment of verbal 
semantic knowledge. Other cognitive 
domains, including calculation, non-verbal 
reasoning (Raven’s Coloured Matrices), 
episodic memory (Camden Pictorial 
Recognition Memory Test) and visuospa-
tial skills, were intact.
Dementia screening bloods and cere-
brospinal fluid analysis (undertaken 
prior to the availability of Aβ42 and tau 
measurements) were normal. An MRI 
scan was reported as showing scattered 
white matter lesions in both cerebral 
hemispheres, presumed secondary to 
mild small vessel disease, with evidence 
of generalised brain atrophy, although the 
scan was unavailable for review.
A diagnosis of semantic dementia was 
made based on the history and pattern of 
her cognitive deficits.
She was next reviewed 5 years later 
when she had deteriorated significantly 
with very limited comprehension and 
frequent use of jargon words, as well 
as presenting with visual agnosia. Her 
behaviour had deteriorated, becoming 
severely apathetic, losing interest in all 
of her previous hobbies, increasingly 
obsessive, particularly with time-keeping, 
markedly disinhibited, and developing 
a sweet tooth. She could no longer do 
housework and struggled with personal 
activities of daily living.
The patient was subsequently lost to 
follow-up and died 10 years after onset 
without being examined at postmortem.
Twenty years after presentation, a DNA 
sample was tested using the Medical 
Research Council (MRC) Dementia 
Gene Panel, a custom next-genera-
tion sequencing technology covering 
17 dementia genes, including common 
FTD-associated genes such as MAPT and 
GRN.1 Samples were tested separately for 
C9orf72 expansions and PRNP octapep-
tide repeat insertions/deletions. Results 
were analysed for known and novel vari-
ants and confirmed by Sanger sequencing.
We discovered a novel PRNP variant 
(R156C, g.4680332C>T), which is 
absent from 141 362 unrelated individ-
uals’ exome and whole-genome sequences 
collated by the Exome Aggregation 
Consortium (http:// gnomad. broadinsti-
tute. org/). The patient was homozygous 
for methionine at codon 129 (129MM). 
No other pathogenic mutations or risk 
factors for neurodegeneration were 
identified. The variant results in the 
replacement of a large, positively charged 
arginine residue,located immediately 
after the first α-helix of the prion protein 
(PrPC), with a smaller polar, uncharged 
cysteine (figure 1). As this amino acid is 
located on the PrPC surface, it is unlikely 
to cause a gross conformational change 
in PrPC. However, cysteines may form 
intermolecular or intramolecular cova-
lent disulphide bonds. Indeed, the two 
wild-type cysteines present in PrPC form a 
disulphide bond, which is essential to the 
fold stability of the protein.3 We hypothe-
sise that the introduction of an additional 
cysteine might disrupt the normal PrPC 
disulphide bond or result in the forma-
tion of intermolecular disulphide bonds, 
as observed previously.4 A similar arginine 
to cysteine mutation, R208C, has been 
found in a single case with CJD.5 A few 
other mutations have been reported in 
the region between first and second α-he-
lices including Q160X, Y163X, D167G 
and D167N, some of which follow a 
very atypical clinical course.6 No muta-
tions have been reported at position 156, 
but in silico modelling (Polyphen, SIFT, 
FATHMM, MutationAssessor, Mutation-
Taster) suggests that this variant is likely 
to be pathogenic. However, Minikel et al7 
demonstrated that the frequency of PRNP 
missense and truncating variants in the 
general population is incompatible with 
the incidence of prion diseases. Novel 
variants thus need to be assessed with 
caution regarding their pathogenicity in 
the absence of segregation or functional 
data despite their rarity.
We report a novel missense mutation of 
PRNP in a patient with semantic dementia, 
which would at present be classified as 
likely pathogenic. Patients with semantic 
dementia would not normally be recom-
mended for genetic studies, particularly 
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of PRNP. The use of next-generation 
sequencing technologies will be increas-
ingly important in elucidating the causes 
of pleiotropic conditions such as familial 
dementia. 
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Figure 1 ribbon representation of the structure of the folded domain of the human prion protein,3 
with α-helices coloured red, β-strands cyan and loops white.  the mutated cysteine side chain of 
residue 156 is shown in yellow. the disulphide bond linking the side chains of the other cysteines 
in the protein (residues 179 and 214) is shown in magenta. this figure was prepared using PyMOL 
(Schrödinger).
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